Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Operating Leases (2021 - 2025)

Organogenesis Holdings (ORGO) has 5 years of Operating Leases data on record, last reported at $22.5 million in Q4 2025.

  • For Q4 2025, Operating Leases fell 10.83% year-over-year to $22.5 million; the TTM value through Dec 2025 reached $22.5 million, down 10.83%, while the annual FY2025 figure was $22.5 million, 10.83% down from the prior year.
  • Operating Leases reached $22.5 million in Q4 2025 per ORGO's latest filing, down from $23.5 million in the prior quarter.
  • Across five years, Operating Leases topped out at $57.1 million in Q1 2021 and bottomed at $20.9 million in Q4 2022.
  • Average Operating Leases over 5 years is $32.6 million, with a median of $27.2 million recorded in 2021.
  • The widest YoY moves for Operating Leases: up 52.12% in 2022, down 55.33% in 2022.
  • A 5-year view of Operating Leases shows it stood at $46.9 million in 2021, then plummeted by 55.33% to $20.9 million in 2022, then increased by 19.6% to $25.1 million in 2023, then rose by 0.58% to $25.2 million in 2024, then decreased by 10.83% to $22.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $22.5 million in Q4 2025, $23.5 million in Q3 2025, and $24.6 million in Q2 2025.